INFAT®, the innovative ingredient that is marketed by Advanced Lipids, a joint venture of AAK and Enzymotec, has been introduced by Advanced Lipids customers into 16 new products globally in this year alone. Contributions from the new products’ launches are expected to start in 2015. INFAT® is a sn-2 Palmitate (OPO) fat ingredient, produced by a patented enzymatic process which enables it to resemble the composition, structure and nutritional value of breast milk. INFAT® ensures an optimal level of sn-2 Palmitate in the infant formula.
INFAT® is the only sn-2 Palmitate (OPO) fat ingredient that has been clinically proven to significantly reduce crying duration mainly in the late afternoon – evening time.
By series of clinical and preclinical trials it was demonstrated that infant formulas containing INFAT® show a beneficial contribution to infant’s health and well-being, relating to enhanced beneficial gut flora, controlled intestinal health, softer stools, increased fat absorption and increased bone strength and as stated above the outstanding latest results of reducing baby crying.
“INFAT® is produced according to the highest standards of quality and safety and the satisfying results indicate that customers recognize it” says Karel Stoschek, CEO Advanced Lipids.
“Leading consumer brands globally rely on INFAT® to provide them an innovative, well-established component with a clinically proven holistic effect of infants’ development and well-being.” says Yoav Kahane, Chairman of Advanced Lipids. “INFAT® creates an opportunity for brand owners to differentiate and to offer excellence and high quality to their consumers so that they can make good, healthy, informed choices for their babies” concludes Mr. Kahane.
About Advanced Lipids
Advanced Lipids is a joint venture of AAK and Enzymotec. For more information, visit